Keyphrases
Human Plasma
90%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
76%
Docetaxel
76%
Anticancer Drugs
72%
Pharmacokinetics
51%
Liquid Chromatography-tandem Mass
46%
Spectrometric Assay
46%
Mass Spectrometry
46%
Breast Cancer
45%
Mouse Plasma
42%
Paclitaxel
39%
Clinical Pharmacology
38%
Cancer Patients
36%
Capecitabine
35%
Taxanes
34%
Bioanalysis
34%
In Cancer
30%
Reversed-phase HPLC
26%
Cytochrome P450 3A (CYP3A)
26%
Echinacea Purpurea
26%
Triple Quadrupole Mass Spectrometer
25%
Protein Precipitation
24%
Ritonavir
23%
Obese children
23%
Lonafarnib
23%
Gemcitabine
23%
Trastuzumab
23%
MTOR Inhibitor
23%
Breast Cancer Treatment
23%
Carboplatin
23%
Quantitative Determination
23%
Population Pharmacokinetics
23%
Acetonitrile
22%
Between-day
21%
Plasma Samples
20%
Limit of Quantification
20%
Doxorubicin
19%
C18 Column
19%
Bioanalytics
19%
Selected Reaction Monitoring
19%
Monitoring Mode
19%
Neutropenia
18%
Formic Acid
18%
Prognostic Biomarker
18%
Rucaparib
17%
Antipsychotics
17%
P-glycoprotein (P-gp)
17%
Phase II Study
16%
Drug Development
16%
Inter-individual Variability
16%
Pharmacokinetic Interaction
16%
Cytochrome P450 3A4 (CYP3A4)
16%
ABCG2
15%
Serum Concentration
15%
Metabolism
15%
Methanol
15%
PARP Inhibitor (PARPi)
15%
AT7519
15%
Respiratory Pathogens
15%
Polymorphism
15%
Reversed Phase
15%
Pharmacokinetic Study
14%
Multi-ethnic
14%
Surface-enhanced Laser Desorption/ionization Time-of-flight Mass Spectrometry (SELDI-TOF-MS)
14%
Sample Handling
14%
Active Metabolite
14%
Electrospray Tandem Mass Spectrometry
14%
Tyrosine Kinase Inhibitor
14%
Human Urine
14%
Clinical Practice
14%
Everolimus
14%
Oral Docetaxel
13%
ATP-binding Cassette Transporter A1 (ABCA1)
13%
Clinical Evaluation
13%
Human Rhinovirus
13%
HPLC-FLD
13%
Pharmacology
13%
Sample Pretreatment
13%
Overexpressing
13%
Regorafenib
13%
Tumor
13%
Fluorescence Detection
13%
Pharmacokinetic Analysis
13%
Analytical Condition
13%
Electrospray Interface
13%
Eluate
13%
Logarithmic Calibration
13%
Early Breast Cancer
13%
Obese Adolescents
13%
Metastatic Breast Cancer
13%
Oncology
13%
Assay Accuracy
13%
Dose Individualization
12%
Serum Samples
12%
Treatment Optimization
12%
Chromatographic Separation
12%
5-fluorouracil (5-FU)
12%
Eribulin Mesylate
12%
Anthracyclines
12%
Isocratic Elution
11%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Docetaxel
80%
Breast Cancer
64%
Malignant Neoplasm
47%
Anticancer Drug
40%
Paclitaxel
39%
Capecitabine
35%
Taxane
34%
Anticarcinogen
33%
Electrospray Ionization
32%
Clinical Study
29%
High Performance Liquid Chromatography
28%
Biological Marker
27%
Pharmacodynamics
26%
CYP3A
26%
Echinacea purpurea
25%
Drug Development
23%
Clinical Pharmacology
23%
Mammalian Target of Rapamycin Inhibitor
23%
Gemcitabine
23%
Infectious Agent
23%
Lonafarnib
23%
Trastuzumab
23%
Methanol
22%
Ritonavir
22%
CYP3A4
20%
Formate
18%
Acetonitrile
18%
Chemotherapy
18%
Neutropenia
17%
Tamoxifen
17%
Combination Therapy
16%
Neoplasm
16%
Side Effect
15%
P-Glycoprotein
15%
Eribulin
15%
Protein Tyrosine Kinase Inhibitor
14%
Effusion
14%
Pharmacotherapy
14%
Clinical Pharmacokinetics
14%
Everolimus
14%
Regorafenib
13%
Doxorubicin
13%
Metastatic Breast Cancer
13%
Active Metabolite
12%
Cohort Study
12%
Fluorouracil
12%
Anthracycline
12%
Lung Alveolus Cell Carcinoma
11%
Olaparib
11%
Lenvatinib
11%
Pregnane X Receptor
11%
Ciclosporin
11%
MDMA
11%
Bendamustine
11%
Enzyme Inhibition
11%
Antipsychotic
11%
Acetylcysteine
11%
Dactolisib
11%
Reverse Phase High Performance Liquid Chromatography
11%
Prospective Cohort Study
11%
Deoxycytidine
11%
Abacavir
11%
Bile Duct Cancer
11%
Cystatin C
11%
Dyspnea
11%
NONMEM
11%
Fluoropyrimidine
11%
Oseltamivir
11%
Ethylenediaminetetraacetic Acid
11%
Adenosine Triphosphate
11%
Carboplatin
11%
Disease Course
11%
2009 H1N1 Influenza
11%
Lamivudine
11%
Ribavirin
11%
Tenofovir
11%
Emtricitabine
11%
Zidovudine
11%
4 Acetamido 5 Amino 3 (1 Ethylpropoxy) 1 Cyclohexene 1 Carboxylic Acid
11%
Liver Dysfunction
11%
Deoxyuridine
11%
Polypeptide
11%
Carboxylesterase
11%
DNA Immunization
11%
Transferase Inhibitor
11%
Hypericum perforatum
11%
Dimethylallyltransferase
11%
Plasmid DNA
11%
Buffer
11%
Histidine
11%
Clinical Trial
10%
Human Rhinovirus
10%
Sorafenib
10%
Doxorubicinol
9%
Diseases
8%
Cytochrome P450
8%
Influenza A (H1N1)
8%
Prevalence
8%
Adverse Event
8%